UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 526, 2022

ChemoCentryx, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-35420	94-3254365
(State or other jurisdictionof incorporation)	(CommissionFile Number)	(IRS EmployerIdentification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

835 Industrial Road, Suite 600, San Carlos, CA		94070
835 Industrial Road, San Carlos, CA		94070
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (650) 210-2900

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~TradingSymbol~~Trading Symbol(s)		Name of each ~~exchangeon~~exchange on which registered
Common Stock, par value $0.001 per share		CCXI		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of ~~1934~~1034 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.02. ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition.~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

OnEffective as of May 526, 2022, upon the recommendation of the Nominating and Corporate Governance Committee and the approval of the stockholders at the annual meeting of stockholders of ChemoCentryx, Inc. ~~issued~~(the a“Company”), ~~press~~David ~~release~~E. ~~announcing~~Wheadon, ~~its~~M.D., ~~financial~~age ~~results~~64, ~~for~~was elected to the ~~first~~Board ~~quarter~~of ~~ended~~Directors ~~March 31,~~(the ~~2022~~“Board”) of the Company as an independent director. ADr. ~~copy~~Wheadon was elected to serve as a Class II director, with an initial term expiring at the 2025 annual meeting of ~~this~~stockholders ~~press~~of ~~release~~the isCompany. ~~attached~~In ~~hereto~~addition, after fulfilling his final term as ~~Exhibit~~a 99Class II director, Henry A.1 McKinnell, Jr., Ph.D. retired from the Board.

InDr. Wheadon ~~accordance~~retired ~~with~~from ~~General~~AstraZeneca ~~Instruction~~PLC ~~B.2~~in of2019 ~~Form~~as ~~8-K,~~Senior ~~the~~Vice ~~information~~President, inGlobal ~~this~~Regulatory ~~Current~~Affairs, ~~Report~~Patient onSafety ~~Form~~and ~~8-K~~Quality Assurance, ~~including~~a ~~Exhibit~~position 99he had held since 2014.1, ~~shall~~Before ~~not~~joining beAstraZeneca, ~~deemed~~Dr. Wheadon ~~“filed”~~held ~~for~~a ~~purposes~~variety of ~~Section 18~~leadership ofroles in the ~~Securities~~healthcare ~~Exchange~~sector, ~~Act~~including ofExecutive ~~1934~~Vice President, asResearch ~~amended~~and (Advocacy at the ~~“Exchange~~Juvenile ~~Act”)~~Diabetes Research Foundation, orSenior ~~otherwise~~Vice ~~subject~~President toof ~~the~~Global ~~liability~~Pharmaceutical ofRegulatory ~~that~~and ~~section,~~Medical ~~nor~~Sciences ~~shall~~at itAbbott beLaboratories, ~~deemed~~and ~~incorporated~~Senior byVice ~~reference~~President inof ~~any~~U.S. ~~filing~~Regulatory ~~under~~Affairs ~~the~~at ~~Securities~~GlaxoSmithKline ~~Act~~Laboratories. ofDr. Wheadon ~~1933,~~has also served as ~~amended~~Senior Vice President, orScientific and Regulatory Affairs at PhRMA, the ~~Exchange~~Washington ~~Act~~D.C.-based Pharmaceutical Industry Research and Manufacturers Association, ~~whether~~during ~~made~~which ~~before~~time orhe ~~after~~interacted with the ~~date~~Food ~~hereof,~~and ~~except~~Drug asAdministration ~~expressly~~(FDA), ~~set~~the ~~forth~~Department byof ~~specific~~Health ~~reference~~and inHuman ~~such~~Services ~~filing~~(HHS), toand ~~this~~the ~~Current~~National ~~Report~~Institutes onof ~~Form~~Health ~~8-K~~(NIH).

~~Item~~Dr. Wheadon 9holds a M.01D. ~~Financial~~from ~~Statements~~Johns Hopkins University School of Medicine and ~~Exhibits~~an A.B. in Biology from Harvard University. He completed his postdoctoral training in Psychiatry at Tufts/New England Medical Center in Boston, Massachusetts. He currently serves on the boards of Karuna Therapeutics Inc., Sotera Health Company, and Vaxart, Inc.

~~(d)~~Item ~~Exhibits~~5.07. Submission of Matters to a Vote of Security Holders

Exhibit No.		Description
99.1		Press Release, dated May 5, 2022
104		Cover Page Interactive Data File (formatted as Inline XBRL).

The Company held its annual meeting of stockholders on May 26, 2022. The following is a brief description of each matter voted upon at the meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable.

To elect the following Class II directors for a three-year term to expire at the 2025 annual meeting of stockholders:


Director Name	For		Against		Abstain		Broker Non-Votes
Geoffrey M. Parker		35,251,509		16,878,334		19,810		7,464,742
James L. Tyree		49,947,587		2,185,377		16,689		7,464,742
David E. Wheadon, M.D.		51,208,441		924,627		16,585		7,464,742

In accordance with the above results, above nominees were elected to serve as directors.

To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022:


For	Against	Abstain	Broker Non-Votes
59,209,659	393,243	11,493	0

In accordance with the above results, the selection of Ernst and Young LLP was approved.

To approve, on an advisory basis, the compensation of our named executive officers:


For	Against	Abstain	Broker Non-Votes
49,983,772	2,020,026	145,855	7,464,742

In accordance with the above results, the compensation of our named executive officers was approved.

Item 7.01.

Regulation FD Disclosure

On May 31, 2022, the Company issued a press release announcing changes to the composition of its Board of Directors. David E. Wheadon M.D. has been elected to the Board as an independent director, and Henry A. McKinnell, Jr., Ph.D., retired from the Board, effective May 26, 2022. A copy of the press release is being furnished as Exhibit 99.1 to this report.

The information contained in this Item 7.01, including the exhibit referenced herein, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01.

Financial Statements and Exhibits

(d)

Exhibits

The following exhibit is furnished herewith:


Exhibit Number		Description

99.1		Press release issued by ChemoCentryx, Inc., dated May 31, 2022.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CHEMOCENTRYX, INC.
Date: May 5, 2022
Date: June 1, 2022
	By:	/s/ Susan M. Kanaya
	Name: Susan M. Kanaya
	Name:	Susan M. Kanaya
	Title: Executive Vice President Chief Financial and Administrative Officer and Secretary
	Title:	Executive Vice President Chief Financial and Administrative Officer and Secretary

Filing Compare · ChemoCentryx, Inc.